Heat shock proteins (hsp's) protect cells from a variety of stresses. Human breast cancer cells may express high levels of hsp27 and hsp70 in particular, which we have found to be associated with general tumor aggressiveness. Preliminary evidence also suggests that hsp's play a role in drug resistance, and understanding the mechanisms involved could lead to clinical strategies to circumvent such resistance and improve patient survival. We initially found that heat shock increases the resistance of breast cancer cells to doxorubicin, while inducing hsp27 and hsp70. Introducing hsp27 cDNA makes the cells resistant to doxorubicin, while blocking hsp27 expression with flavones (e.g. quercitin) reverses resistance. We now need to determine whether hsp70 plays a similar role. We also plan to further investigate means of modulating hsp27 expression for therapeutic benefit by manipulating its regulatory promoter system - we have already identified key elements of the promoter region to be targeted, along with a novel DNA-binding protein which binds one of these elements. We will examine mechanisms which may be involved in the association of hsp's with drug resistance, and confirm the association in clinical breast cancer specimens from doxorubicin-resistant vs. naive patients.
Our Specific Aims are: (1) To confirm our preliminary finding that hsp70 may also play a role in doxorubicin resistance in human breast cancer cells. We will use antisense oligonucleotides to inhibit expression of both hsp70 and its constitutive cognate hsc70 in breast cancer cells, and full-length cDNAs to induce overexpression, determining drug resistance in soft agar cloning assays and in vivo nude mouse studies. (2) To further develop pharmacologic means (flavone inhibition) and molecular means (promoter studies) to circumvent hsp27-induced doxorubicin resistance. (3) To search for mechanisms associated with this resistance, focusing in particular on the role of topoisomerase II. (4) To translate these findings to the clinical setting by determining the relationship of hsp27 and hsp70 with clinical doxorubicin resistance. We will compare hsp levels in a set of 100 doxorubicin-resistant metastases vs. 100 naive breast cancer specimens, and will also correlate hsp levels with clinical outcome in a prospective, randomized adjuvant clinical trial (SWOG 8897) involving doxorubicin. All of this will prepare for a Phase I clinical trial directed at circumventing hsp-induced doxorubicin resistance using the pharmacologic agent quercitin, though the trial itself is not a part of the present proposal, and will also suggest other approaches for reversing resistance to this otherwise most useful drug in breast cancer treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA058183-08S4
Application #
6464616
Study Section
Project Start
1999-08-30
Project End
2003-07-31
Budget Start
Budget End
Support Year
8
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Type
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Kaochar, Salma; Mitsiades, Nicholas (2018) A Novel Mechanism to Drive Castration-Resistant Prostate Cancer. Trends Endocrinol Metab 29:366-368
Bhat, Raksha R; Yadav, Puja; Sahay, Debashish et al. (2018) GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer. Breast Cancer Res Treat 170:279-292
Guarducci, Cristina; Bonechi, Martina; Benelli, Matteo et al. (2018) Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. NPJ Breast Cancer 4:38
Rimawi, Mothaffar F; De Angelis, Carmine; Contreras, Alejandro et al. (2018) Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat 167:731-740
Sukumaran, Sujita; Watanabe, Norihiro; Bajgain, Pradip et al. (2018) Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. Cancer Discov 8:972-987
Yu, L; Liang, Y; Cao, X et al. (2017) Identification of MYST3 as a novel epigenetic activator of ER? frequently amplified in breast cancer. Oncogene 36:2910-2918
Guven, Adem; Villares, Gabriel J; Hilsenbeck, Susan G et al. (2017) Carbon nanotube capsules enhance the in vivo efficacy of cisplatin. Acta Biomater 58:466-478
Veeraraghavan, Jamunarani; De Angelis, Carmine; Reis-Filho, Jorge S et al. (2017) De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. Breast 34 Suppl 1:S19-S26
Xu, Xiaowei; De Angelis, Carmine; Burke, Kathleen A et al. (2017) HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res 23:5123-5134
Hertz, D L; Kidwell, K M; Hilsenbeck, S G et al. (2017) CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study. Breast Cancer Res Treat 166:277-287

Showing the most recent 10 out of 306 publications